{
  "id": 12900355,
  "title": "Ono pays Biohaven $80M for protein degrader; UK pulls Valneva's chikungunya shot",
  "url": "https://urgent.news/2026/10/08/ono-pays-biohaven-80m-for-protein-degrader-uk-pulls-valnevas",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-08T15:30:49.000Z",
  "source": {
    "name": "Endpoints News",
    "slug": "endpoints-news",
    "url": "https://endpoints.news/ono-pays-biohaven-80m-for-protein-degrader-uk-pulls-valnevas-chikungunya-shot/"
  },
  "original_language": "en",
  "account": null,
  "summary": "Plus news about ADC Therapeutics, Atrium Therapeutics, Bristol Myers, Novartis and Pfizer. Biohaven partners with Ono: Tokyo-based Ono Pharmaceutical has agreed to pay Biohaven $80 million upfront to license its pan-IgG ...",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}